Brenda Irwin

Brenda Irwin is a seasoned venture capital professional with extensive experience in health technology and investment. Currently serving as the Managing General Partner at Relentless Venture Fund, Brenda focuses on early-stage investments in chronic disease management and preventive health technology solutions. Additionally, Brenda holds leadership roles as Committee Chair of Horizon-AI at the Digital Technology Supercluster and as Independent Project Selection Committee Chair for the Canadian Medical Isotope Ecosystem Development Fund. With a background in angel investing through Relentless Pursuit Partners and previously at Angel Links Capital, Brenda played a pivotal role in high-value investments, such as in Celator Pharmaceuticals during time at BDC. Educational credentials include a Master of Business specializing in Information Technology from the Sauder School of Business at the University of British Columbia, along with multiple degrees in education and biology from Queen's University and the University of Guelph.